Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 11Ifosfamide 10Radiotherapy 8Imatinib Mesylate 4Filgrastim 4Etoposide 3Chemotherapy, Adjuvant 3Carboplatin 3pegfilgrastim 2cixutumumab 2belinostat 2Vincristine 2Sunitinib 2Radiotherapy, Conformal 2Epirubicin 2Dactinomycin 2Cyclophosphamide 2temsirolimus 1soblidotin 1saracatinib 1romidepsin 1ribociclib 1reolysin 1perifosine 1pazopanib 1indolepropanol phosphate 1exatecan 1brostallicin 1Watchful Waiting 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fibrosarcoma × soblidotin × Clear all
NCT00064220 2012-05-16

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Daiichi Sankyo

Phase 2 Completed
Sarcoma

Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡